- Home
- PVLA vs IMMP Comparison
PVLA vs IMMP Comparison
Compare PVLA & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PVLA
- IMMP
- Stock Information
- Founded
- PVLA 2015
- IMMP 1987
- Country
- PVLA United States
- IMMP Australia
- Employees
- PVLA N/A
- IMMP N/A
- Industry
- PVLA Biotechnology: Pharmaceutical Preparations
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- PVLA Health Care
- IMMP Health Care
- Exchange
- PVLA Nasdaq
- IMMP Nasdaq
- Market Cap
- PVLA 285.2M
- IMMP 244.5M
- IPO Year
- PVLA N/A
- IMMP N/A
- Fundamental
- Price
- PVLA $36.55
- IMMP $1.72
- Analyst Decision
- PVLA Strong Buy
- IMMP Buy
- Analyst Count
- PVLA 8
- IMMP 1
- Target Price
- PVLA $47.50
- IMMP $7.00
- AVG Volume (30 Days)
- PVLA 176.0K
- IMMP 74.8K
- Earning Date
- PVLA 08-15-2025
- IMMP 02-27-2025
- Dividend Yield
- PVLA N/A
- IMMP N/A
- EPS Growth
- PVLA N/A
- IMMP N/A
- EPS
- PVLA N/A
- IMMP N/A
- Revenue
- PVLA N/A
- IMMP $3,019,249.00
- Revenue This Year
- PVLA N/A
- IMMP $50.37
- Revenue Next Year
- PVLA N/A
- IMMP N/A
- P/E Ratio
- PVLA N/A
- IMMP N/A
- Revenue Growth
- PVLA N/A
- IMMP 24.11
- 52 Week Low
- PVLA $11.17
- IMMP $1.32
- 52 Week High
- PVLA $40.50
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- PVLA N/A
- IMMP 50.65
- Support Level
- PVLA N/A
- IMMP $1.60
- Resistance Level
- PVLA N/A
- IMMP $1.81
- Average True Range (ATR)
- PVLA 0.00
- IMMP 0.06
- MACD
- PVLA 0.00
- IMMP 0.01
- Stochastic Oscillator
- PVLA 0.00
- IMMP 52.17
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.